<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00485576</url>
  </required_header>
  <id_info>
    <org_study_id>C07-002</org_study_id>
    <nct_id>NCT00485576</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Mild Allergic Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to designed to test the role of complement in the late asthmatic response to
      allergen challenge in mild asthma, as an indicator of the possible role of complement in the
      broader asthmatic population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Allergen-induced late asthmatic response as measured by the AUC of FEV1 from 3 to 7 hours post-allergen challenge</measure>
    <time_frame>7 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>At 24 hours post-allergen challenge; treatment comparison of allergen-induced changes from baseline in sputum eosinophils and metachromatic cells</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergen-induced airway responsiveness 24 hours post-allergen challenge as primary interest; 72 hour assessment timepoint will be supportive</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum % decrease in FEV1 from 3 to 7 hours post-allergen challenge</measure>
    <time_frame>7 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% decrease of FEV1 at 24 hours post-allergen challenge</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC and maximum % fall of FEV1 from 0-3 hours post-allergen challenge</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Allergic Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eculizumab</intervention_name>
    <description>eculizumab 600 mg or matching placebo iv infusion.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with stable, mild, allergic asthma;

          -  history of episodic wheeze and shortness of breath;

          -  sexually active women of childbearing potential must use contraceptive during the
             entire duration of study;

          -  willing and able to give informed consent;

          -  positive methacholine challenge;

          -  positive skin prick test to common aeroallergens;

          -  positive allergen-induced early and late phase bronchoconstrictor response

          -  FEV1 at least 70% of predicted value;

          -  PC20 at baseline that is within 1 doubling dose of that measured during screening

        Exclusion:

          -  active bacterial infection;

          -  respiratory tract infection or worsening of asthma within 28 days

          -  use of inhaled or topical steroids within 28 days or use of systemic corticosteroids
             within 90 days;

          -  use of cromoglycate, nedocromil, leukotriene receptor antagonists and inhibitors of
             5-lipoxygenase within 14 days;

          -  use of antihistamines, immunosuppressives, or any medications that interact with
             eculizumab;

          -  use of theophylline-containing agents (any type), long-acting beta 2-agonists
             (salmeterol, formoterol) or long-acting anticholinergics within 14 days;

          -  use of NSAIDs prior to spirometry;

          -  use of tobacco products currently or within the previous 12 months; or smoking history
             &gt; 10 pack-years;

          -  lung disease other than mild allergic asthma;

          -  patients with LAR who have not been vaccinated against Neisseria meningitidis;

          -  hepatitis B or HIV infection;

          -  parasitic infection;

          -  participation in any other investigational drug trial;

          -  pregnant or breast feeding women, or intending to conceive during the course of trial;

          -  known hypersensitivity to the treatment drug or any of its excipients;

          -  history of illicit drug use or alcohol abuse within previous year;

          -  any clinically significant abnormality on screening lab test results;

          -  abnormal chest X-ray;

          -  chronic use of any other medication for treatment of allergic lung disease other than
             short-acting beta2-agonists or ipratropium bromide;

          -  any medical condition that might interfere with the subject's participation in the
             study or confound the assessment of the subject;

          -  unwilling or inability to comply with the study protocol for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henk-Andre Kroon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alexion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Laval</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2007</study_first_submitted>
  <study_first_submitted_qc>June 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2007</study_first_posted>
  <last_update_submitted>January 14, 2009</last_update_submitted>
  <last_update_submitted_qc>January 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2009</last_update_posted>
  <responsible_party>
    <organization>Alexion Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

